CHIMI 5121 - Chimie bio inorganique: Bibliographie

Bibliographie

Inorganic Chemistry, Duward Shriver, Peter Atkins, 3th Edition;
Bioinorganic Chemistry, A short Course, Rosette M. Roat-Malone, 1 & 2th Edition.
Rosenberg B, Camp LV and Krigas T (1965) Inhibition of cell division of Escherichia coli by

electrolysis products from platinum electrode; Nature, 205, 698-699.

Rosenberg B (1978) Platinum complex-DNA interactions and anticancer activity; Biochimie, 60,859-867.
Jamieson ER and Lippard SJ (1999) Structure, recognition and processing of cisplatin-DNA

Adducts; Chem Rev, 99, 2467-2498.

Bentefrit F (1996) Analogues du cisplatine: quelques composés formés par le platine (II) et (IV) oupalladium (II) avec deux médicaments de la famille des biguanides (metformine et proguanil), thèsede l'Université PARIS XI.
Scott J and Bradbury R (1994) Pharmacokinetic dosing of carboplatin; Fla J Hosp Pharm, 14, 17-18.
Coste F, Malinge J-M, Serre L, Shepard W, Roth M, Leng M and Zelwer C (1999) Crystal

structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63Å

resolution: hydratation at theplatinated site; Nucleic Acid Res, 27, 1837-1846.

Ishikawa T and Ali-Osman F (1993) Glutathione-associated cis-diamminedichloroplatinum(II)

metabolism and ATP-dependent efflux from leukemia cells: molecular characterization of

glutathione-platinum complex and its biological significance; J Biol Chem, 268, 20116-20125.

Dedon PC (1987) Characterization of the reactions of platinum antitumour agents with biologic

and non biologic sulfur containing nucleophiles; Biochem Pharm, 36, 1955-1964.

Wong E (1999) Current status of platinum-based antitumour drugs; Chem Rev, 99, 2451-2466.
Chu G (1994) Cellular responses to cisplatin; J Biol Chem, 269, 787-790.
Micetich KC, Barnes D and Erickson LC (1985) A comparative study of the cytotoxicity and

DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum (II) and cisdiamminedichloroplatinum (II) on L1210 cells; Cancer Res, 45, 4043-4047.

Ongeri S (1999) Synthèse de composés carboxyliques 1,2-diaminés d'intérêt biologique, thèse de l'Université René Descartes de Paris.
Benaji B, Dine T, Luyckx M, Brunet C, Goudaliez F, Mallevais ML, Cazin M, Gressier B and
Cazin JC (1994) Stability and compatibility of cisplatin and carboplatin with PVC infusion bags; J Clin Pharm Ther, 19, 95-100.
Hadfield JA, McGown AT, Dawson MJ, Thatcher N and Fox BW (1993) The suitability of

carboplatin solutions for 14-day continuous infusion by ambulatory pump: an HPLC- dynamic FAB study; J Pharm Biomed Anal, 167, 723-727. Lederer M and Leipzig-Pagani E (1998) A note on the solution chemistry of carboplatin in aqueous solutions; Int J Pharm, 167, 223-228.

Burchenal JH, Iranai G, Kern K and al. e (1980) 1,2-Diaminocyclohexane platinum derivatives of potential clinical value; Recent Res Cancer Res, 74, 146-155.
Desoize B and Madoulet C (2002) Particular aspects of platinum coumpounds used at present in cancer treatment; Critical review in oncology/ hematology, 42, 317-325.
Scheeff ED, Briggs JM and Howell SB (1999) Molecular modeling of the intrastrand guanineguanine DNA adducts produced by cisplatin and oxaliplatin; Mol Pharmacol, 56, 633-643.
Judson I and Kelland LR (2000) New developments and approaches in the platinum Arena; Drugs, 59 suppl 4, 29-36.
Akasa H, Togashi M, Nishio Y and al. e (1992) Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer and trasitional-cell carcinoma of the urinary tract.; Cancer Chemother Pharmacol, 31, 187-192.
Sasaki Y, Tamura T, Eguchi K and al. e (1989) Pharmacokinetics of (glycolate-O,O')-diammine platinum(II), a new platinum derivative, in comparison with cisplatin and carboplatin; Cancer Chemother Pharmacol, 23, 243-246.
Rosenberg B, Camp LV, Grinley EB and Thomson AJ (1967); J Biol Chem, 242, 1347.
Lansiaux A (2000) Le JM216, un dérivé du platine actif par voie orale; Bull Cancer, 87, 531-536.
Reardon JT, Vaisman A, Chaney SG and Sancar A (1999) Efficient Nucleotide Excision Repair of cisplatin, Oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(iv) (JM216) Platinum intrastrand DNA diadducts; Cancer Res, 59, 3968-3971.
Fokkema E, Groen HJM, Helder MN, Vries EGEd and Meijer C (2002) JM216-, JM118, and
cisplatin-nducd cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and P53 status in human tumour cell lines with different sensitivities to cisplatin; Biochem Pharm, 63,1989-1996.
Holford J, Beale PJ, Boxall FE, Sharp SY and Kelland LR (2000) Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines; Eur J cancer, 36, 1984-1990. Kelland LR, Sharp SY, O'Neill C, Raynaud FI, Beale PJ and Judson IR (1999) Mini-review:discovery and development of platinum complexes designed to circumvent cisplatin resistance; J Inorg Biochem, 77, 111-115.
Gore ME, Atkinson RJ, Thomas H, Cure H, Rischin D, Beale P, Bougnoux P, Dirix L and Smit

WM (2002) A phase II trial of ZD0473 in platinum-pretreated ovarian cancer; Eur J cancer, 38,

2416-2420.

Brabec V, Kasparkova J, Vrana O, Novakova O, Cox JW, Qu Y and Farrell N (1999) DNA

modifications by a novel bifunctional trinuclear platinum phase I anticancer agent biochemistry, 38,6780-6790.

Calvert PM, Highley MS, Hughes AN, Plummer ER, Azzabi AST, Verrill MW, Camboni MG,

Verdi E, Bernareggi A, Zucchetti M, Robinson AM and Calvert AH (1999) A phase I study of a

novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumor; Clin Cancer Res, 5, 333.

Kasparkova J, Zehnulova J, Farrell N and Brabec V (2002) DNA interstrand Cross-kinks of the

novel antitumour trinuclear platinum complex BBR3464; J Biol Chem, 277, 48076-48086.

Marzano C, Trevisan A, Giovagnini L and Fregona D (2002) Synthetis of a new platinum (II)

complex : anticancer activity and nephrotoxicity in vitro; Toxicology in vitro, 16, 413-419.

Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M and Gamelin E (2000) Clinical Pharmaceutics of oxaliplatin: A critical review; Clin cancer Res, 6, 1205-1218.
Kratochwil NA, Iranov AI, Patriarca M, Parkinson JA, Gouldsworthy AM, Murdoch PdS and

Sadler PJ (1999) Surprising reactions of iodo Pt(IV) and Pt(II) complexes with human albumin: detection of cys 34 sulfenic acid; J Am Chem Soc, 121, 8193-8203.

Reedjik J (1999) Why does cisplatin reach guanine-N7 with competing S-donor ligands available inthe cell? ; Chem Rev, 99, 2499-2510.
Garcia-seijo I, Habtemariam A, Murdoch PdS, Gould RO and Garcia-Fernandez E (2002) Fivecoordinate aminophosphine platinum (II) complexes containing cysteine derivatives as ligands; Inorg Chem acta, 335, 52-60.
Murdoch PdS, Randford JD, Sadler PJ and Berners-Price SJ (1993) Cis-trans isomerization of

[Pt(L-methionine)2]: Metabolite of the anticancer drug cisplatin; Inorg Chem, 32, 2249-2255.

Melvik JE and Pettersen EO (1987) Reduction of cis-dichlorodiammineplatinum-induced cell

inactivation by methionine; Inorg Chem Acta, 137, 115-118.

Allsopp MA, Sewell GJ, Rowland CG, Riley CM and Schowen RL (1991) The degradation of

carboplatin in aqueous solutions containing chloride or other selected nucleophiles; Int J pharm, 69, 197-210.

Howell SB and Taetle R (1980) Effect of sodium thiosulfate on cis-dichlorodiammineplatinum (II) toxicity and antitumor activity in L1210 leukemia; Cancer Treat rep, 64, 611-616.
Bodenner DL, Dedon PC, Keng PC and Borch RF (1986) Effect of diethyldithiocarbamate on cisdiamminedichloroplatinum(II)-induced cytotoxicity, DNA cross-linking, and gamma-gluthamyl transpeptidase inhibition; Cancer Res, 46, 2745-2750.
Bodenner DL, Dedon PC, Keng PC, Katz JC and Borch RF (1986) Selective protection against cis-Diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by
diethyldithiocarbamate; Cancer Res, 46, 2751-2755.
Borch RF and Pleasants ME (1979) Inhibition of cis-platinum nephrotoxicity by
diethyldithiocarbamate rescue in a rat model; Proc Natl Acad Sci USA, 76, 6611-6614.
Daley-Yates PT and McBrien DCH (1982) The inhibition of renal ATPase by cisplatin and some biotransformation products; Chem Biol Interact, 40, 325-334.
Castegnaro M (1985) Method 10: destruction of cisplatin by reaction with sodium